Clovis Oncology (NASDAQ:CLVSQ) Versus Oncotelic Therapeutics (OTCMKTS:OTLC) Head-To-Head Contrast
Clovis Oncology (NASDAQ:CLVSQ – Get Rating) and Oncotelic Therapeutics (OTCMKTS:OTLC – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two co
Defense WorldApr 13, 2023 01:42 ET
Clovis Oncology (CLVSQ) & Its Peers Head to Head Survey
Clovis Oncology (NASDAQ:CLVSQ – Get Rating) is one of 981 public companies in the "Pharmaceutical preparations" industry, but how does it contrast to its competitors? We will compare Clovis Oncology t
Financial News LiveMar 2, 2023 04:03 ET
Financial Contrast: Clovis Oncology (CLVSQ) Versus Its Competitors
Clovis Oncology (NASDAQ:CLVSQ – Get Rating) is one of 981 public companies in the "Pharmaceutical preparations" industry, but how does it weigh in compared to its competitors? We will compare Clovis O
Defense WorldFeb 28, 2023 02:13 ET
Clovis Oncology (NASDAQ:CLVS) Research Coverage Started at StockNews.com
Equities research analysts at StockNews.com initiated coverage on shares of Clovis Oncology (NASDAQ:CLVS – Get Rating) in a research report issued on Thursday. The brokerage set a "hold" rating on th
Defense WorldJan 12, 2023 03:21 ET
Clovis Oncology (NASDAQ:CLVS) Earns Hold Rating From Analysts at StockNews.com
StockNews.com initiated coverage on shares of Clovis Oncology (NASDAQ:CLVS – Get Rating) in a research note issued to investors on Tuesday. The firm issued a hold rating on the biopharmaceutical comp
kopsourceDec 30, 2022 01:52 ET
Delisting of Securities of Tuscan Holdings Corp. II; Clovis Oncology, Inc.; ZyVersa Therapeutics, Inc.; Otonomy, Inc., and Forward Pharma A/S From The Nasdaq Stock Market
NEW YORK, Dec. 28, 2022 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock, unit, and warrant of Tuscan Holdings Corp. II. Tuscan Holdings Corp. II's securities were
GlobeNewswireDec 28, 2022 16:06 ET
Clovis Oncology (NASDAQ:CLVS) Now Covered by StockNews.com
StockNews.com began coverage on shares of Clovis Oncology (NASDAQ:CLVS – Get Rating) in a research report sent to investors on Monday. The firm issued a hold rating on the biopharmaceutical company's
kopsourceDec 23, 2022 02:21 ET
Zacks.com Featured Highlights Include Clovis Oncology, NiSource, DocuSign, Root and Endava
Yahoo FinanceDec 22, 2022 11:33 ET
Express News | News On Clovis Oncology Inc. (CLVS) Now Under CLVSQ
Moomoo 24/7Dec 21, 2022 17:08 ET
StockNews.com Initiates Coverage on Clovis Oncology (NASDAQ:CLVS)
Analysts at StockNews.com began coverage on shares of Clovis Oncology (NASDAQ:CLVS – Get Rating) in a research note issued to investors on Monday. The firm set a "hold" rating on the biopharmaceutica
Defense WorldDec 19, 2022 03:11 ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersPLx Pharma (NASDAQ:PLXP) stock increased by 10.6% to $0.23 during Wednesday's after-market session. The market value of their outstanding shares is at $6.5 million. Clovis Oncology (NASDAQ:CLVS
Benzinga Real-time NewsDec 14, 2022 16:33 ET
Why Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving Premarket
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) shares rose 150.9% to $0.6313 in pre-market trading after the company entered into a definitive merger agreement with GRI Bio.Crown ElectroKinetics C
Benzinga Real-time NewsDec 14, 2022 06:32 ET
Stocks That Hit 52-Week Lows On Tuesday
 On Tuesday, 49 companies hit new 52-week lows. Key Facts About Today's 52-Week Lows: Tesla (NASDAQ:TSLA) is the largest company in terms of market cap to set a new 52-week low this morning.The sma
Benzinga Real-time NewsDec 13, 2022 12:42 ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersOpGen (NASDAQ:OPGN) stock increased by 242.3% to $0.43 during Tuesday's regular session. OpGen's stock is trading at a volume of 169.2 million shares as of 12:30 EST. This is 40400.7% of its av
Benzinga Real-time NewsDec 13, 2022 12:32 ET
Novartis Bids $681 Million To Buy Cancer Drug From Bankruptcy Filer Clovis Oncology
10:26 PM EST, 12/12/2022 (MT Newswires) -- A Novartis (NOVN.SW) unit offered up to $680.8 million to buy Clovis Oncology's experimental cancer drug as the latter filed for bankruptcy in the US on Mond
MT NewswiresDec 12, 2022 22:28 ET
Clovis Enters Bankruptcy With Deal to Sell Cancer-Drug Candidate to Novartis -- WSJ
By Jonathan Randles Clovis Oncology Inc., maker of the ovarian and prostate cancer drug Rubraca, filed for bankruptcy over the weekend with a proposed deal in hand to sell its rights to a cancer ther
Dow JonesDec 12, 2022 14:06 ET
Stocks That Hit 52-Week Lows On Monday
 Monday saw 196 companies set new 52-week lows. Areas of Interest About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week low was Brookfield Asset Mgmt (NYSE:BAM
Benzinga Real-time NewsDec 12, 2022 10:52 ET
Cancer Focused Clovis Oncology Files For Bankruptcy
Clovis Oncology Inc (NASDAQ:CLVS) has voluntarily initiated a Chapter 11 proceeding in the U.S. Bankruptcy Court and will seek to sell its assets through a court-supervised sales process.The Debtors h
Benzinga Real-time NewsDec 12, 2022 07:32 ET
Clovis Stock Slumps Amid Chapter 11 Filing, to Sell FAP-2286 to Novartis for $50M Upfront
Seeking AlphaDec 12, 2022 06:40 ET
Clovis Oncology Files for Chapter 11 Protection, and Says It Will Sell Assets
Clovis Oncology Files for Chapter 11 Protection, and Says It Will Sell Assets
Dow JonesDec 12, 2022 06:33 ET
No Data
No Data